Tools4Patient

Alvaro Pereira has held the position of Chief Scientific Officer at Tools4Patient since its inception in 2013. Dr.Pereira holds a Ph.D. in Biochemistry from the University of Brussels. Dr. Pereira continued his academic research as a research fellow in the Bioorganic Chemistry and Neurophysiopathology departments at the same institution.

He began his industrial career at Eli Lilly and Company in the Clinical Pharmacology Department. Throughout his industrial career, he worked in clinical pharmacology with increasing responsibilities from individual Phase I studies through entire early-stage development programs (including proof of concept Phase IIa studies) for novel CNS agents. In 2007 he joined Aepodia, a consultancy clinical research organization where he ran the early-stage development section which comprised studies all studies from first-in-human through Phase IIb proof of concept including biomarker validation/development in a variety of different therapeutic areas.

John C. Bloom holds a B.S. degree in biology from the University of Pittsburgh and doctorates in veterinary medicine and experimental hematology from the University of Pennsylvania. He completed his postdoctoral training at Jefferson Medical College in hematology/oncology and served on the Faculty of the University of Pennsylvania School of Veterinary Medicine as Chief, Clinical Laboratory Medicine, before joining Smith Kline & French Laboratories as Associate Director of Pathology. He later joined Lilly Research Laboratories as Head, Clinical Pathology, in the Toxicology Division, and subsequently moved to the Medical Division, where he established the departments of Clinical Laboratory Medicine, Experimental Medicine and Clinical Diagnostic Services. As Executive Director and Distinguished Medical Fellow, Diagnostic and Experimental Medicine, he was responsible for routine laboratory, ECG, imaging and specimen banking support for global clinical development; and novel clinical biomarker discovery, validation and application in the Division of Translational Medicine and pharmacogenomics. Upon his retirement from Lilly in 2009 he established Bloom Consulting Services, LLC and was appointed Special Consultant, Office of the Center Director, FDA. Dr. Bloom serves on several Scientific Advisory Committees for pharmaceutical, diagnostic and pharmaceutical services companies and holds adjunct academic appointments at the University of Pennsylvania and Purdue University.

Dr Didier Bouhassira (MD, PhD) has been trained in neurology and neurophysiology in Paris. He has been involved in both basic and clinical research on pain and is currently Director of Research at the National Institut for Health and Medical Research (INSERM). He is associate attending neurologist in the Pain Clinic at Ambroise Paré hospital in Boulogne-Billancourt and director of the laboratory of “Pathophysiology and Clinical Pharmacology of Pain” (INSERM U-987).

Didier Bouhassira is an active member of several international associations or societies and is the immediate past president of the French Pain Society. He is field editor for the European Journal of Pain and associate editor for several scientific journals including Pain. He has co-authored over 180 articles in peer-reviewed journals and has written a number of book chapters devoted to the pharmacology and pathophysiology of pain.

Dr. Dube holds an MD in Psychiatry from King George’s Medical College. Dr. Dube’s clinical and academic career started at the Lafayette Clinic (Wayne State University) in Detroit and was on staff there for 10 years. Dr.Dube then moved to the Western Psychiatric Institute and Clinic at the University of Pittsburgh as Adjunct Associate Professor of Psychiatry. In 2001 he joined the Indiana University School of Medicine as Adjunct Clinical Professor of Psychiatry. He has received several teaching awards including the prestigious Nancy Roeske Award from the American Psychiatric Association and the Excellence in Teaching Award from the Association of Academic Psychiatry. In 2014, Dr. Dube was appointed as a Consulting Associate Professor of Psychiatry at the Stanford University School of Medicine and Behavioral Sciences and continues to hold adjunct appointments at IU School of Medicine and the University of Pittsburgh. Dr Dube’s industrial carrier started at Eli Lilly and Company in 2001 as Medical Director in the late-stage division and finishing as Senior Medical Fellow. Dr. Dube contributed to the development of several novel compounds for the treatment of severe mental illnesses. Additional he has lead the Phase 2 program for chronic pain medications at Theravance Biopharma and recently he has joined Avanir where is responsible for the CNS pipeline as Vice President, Clinical Development. Dr Dube is widely published and is a member of several international medical organizations.

Dr. Buyse holds degrees in engineering and statistics from the Brussels University, management from the Cranfield School of Management and a doctorate in biostatistics from Harvard University. Dr. Buyse is a founder and Chairman of IDDI, and Associate Professor of Biostatistics at the Hasselt University. Dr. Buyse was the recipient of several research fellowships in Belgium, the US, and Japan. He is the past President of the International Society for Clinical Biostatistics, President of the Quetelet Society, and Fellow of the Society for Clinical Trials. He worked at the EORTC (European Organization for Research and Treatment of Cancer) in Brussels and at the Dana Farber Cancer Institute in Boston prior to founding IDDI in 1991.

Jean Stephenne holds an MSc in Chemistry and Bioindustries from Gembloux/Liège University and obtained an MBA in Management from Louvain-la-Neuve University. Mr. Stephenne joined SmithKline-RIT., where he held positions with increasing leadership responsibilities in the Vaccines Division and was ultimately chosen to become President and General Manager of GlaxoSmithKline Biologicals. During his nearly 40 years at GSK, he steered the company through a series of mergers and acquisitions to create one of the leading global vaccine companies. He retired from GSK in 2012. Today many companies take advantage of Mr. Stephenne’s remarkable industrial experience. His experience has also led him to preside over the Walloon Union of Companies from 1997 to 2000 where he currently still serves on the Board of Administrators.